In this Deep Dive Session, Professor Arnon Kater from the University of Amsterdam provides an in-depth discussion on the treatment of chronic lymphocytic leukemia (CLL) with a focus on novel agents and their impact on disease progression. He discusses the effectiveness of various treatment regimens, including the use of venetoclax, ibrutinib, and CAR-T cell therapy, and highlights the importance of disease control prior to conditioning for allogeneic transplant. The session concludes with a Q&A segment.